Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies-Reference-Cited by-同舟云学术

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

Published:2021-06-26 Issue:5 Volume:110 Page:1261-1272
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharmacol Ther

Author:

Jamois Candice¹,Gibiansky Ekaterina²,Gibiansky Leonid²,Chavanne Clarisse¹,Morcos Peter N.¹,McIntyre Christine³,Barrett Martin³,Lundberg Linda⁴,Zharkov Artem⁵,Boehnke Axel⁴,Frey Nicolas¹

Affiliation:

1. Clinical Pharmacology Pharmaceutical Sciences Pharma Research and Early DevelopmentRoche Innovation Center Basel Basel Switzerland

2. QuantPharm LLC North Potomac Maryland USA

3. Pharma Research and Early Development Roche Innovation Center Welwyn Welwyn Garden City UK

4. Pharma Development Clinical Oncology F. Hoffmann‐La Roche Ltd Basel Switzerland

5. Pharma Development Medical Affairs F. Hoffmann‐La Roche Ltd Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2308

Reference52 articles.

1. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

2. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

3. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

4. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications;Annals of Oncology;2023-08

3. Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology;Journal of Oncology Pharmacy Practice;2022-11-08

4. Model‐Informed Drug Development: Connecting the Dots With a Totality of Evidence Mindset to Advance Therapeutics;Clinical Pharmacology & Therapeutics;2021-10-17